Personalis, Inc.
Government Contracts & Awards
PERSONALIS, INC.: EO 14398
$18,290,000Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Adobe and Jet2 Partner to Deliver Agentic AI-Powered Personalised Experiences to Millions of Jet2 Holidaymakers
Adobe — the global technology leader that unleashes creativity, productivity and customer experiences through innovative tools and platforms — and Jet2, the UK's largest tour operator and third largest airline, have today announced a multi-year strategic partnership set to redefine the holiday experience for millions of customers. The partnership brings together Jet2's award-winning VIP customer experience and its 10 million myJet2 customers, with Adobe's industry-leading Customer Experience Orc
Clay completes $115m Series D, valued at $7.1bn
Clay offers technology designed to help businesses identify potential customers, monitor market signals, and personalise outreach.
Helfie AI Appoints John Rego as Chief Financial Officer
Helfie AI ("Helfie"), an AI-powered preventative network transforming global healthcare by delivering personalised screening for all via mobile, today announced the appointment of John Rego as Chief Financial Officer.
Helfie AI Appoints John Rego as Chief Financial Officer
Helfie AI ("Helfie"), an AI-powered preventative network transforming global healthcare by delivering personalised screening for all via mobile, today announced the appointment of John Rego as Chief Financial Officer.
What’s Going On With Tempus AI Stock on Monday?
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.
Tempus to buy cancer test-maker Personalis for $1.5B
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
Visa, a world leader in digital payments today announced a Memorandum of Understanding (MoU) with Trip.com Group, marking a strategic collaboration to power richer travel experiences for Asia Pacific consumers. The MoU will harness Visa's global payments network and Trip.com Group's extensive ecosystem, enabling travellers to discover personalised recommendations, access offers for dream destinations and transact seamlessly on their journeys.
Congressional Trades in $PSNL
No disclosed congressional trades found in $PSNL.
Insider Trades (Form 4)
Chen Richard
Hall Christopher M
Tachibana Aaron
Moore Stephen Michael
Chen Richard
Hall Christopher M
Tachibana Aaron
Tachibana Aaron
Key People
Chen Richard
President and CMO
Tachibana Aaron
CFO AND COO
Hall Christopher M
Chief Executive Officer
BOWMAN A BLAINE
Director
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro